Hepatocyte growth factor signaling in cancer metastasis

Current Signal Transduction Therapy

Volumn 6, Issue 2, 2011, Pages 180-190

  Martin, Tracey A ^a   Mason, Malcolm D ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Cancer; HGF; Metastasis; Signaling

Indexed keywords

ANGIOGENESIS INHIBITOR; BETA CATENIN; BINDING PROTEIN; CRIZOTINIB; DELPHINIDIN; E 7050; EZRIN; FOCAL ADHESION KINASE; GRB2 ASSOCIATED BINDING PROTEIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MOESIN; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NK4; PANITUMUMAB; PAXILLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA1; PROTEIN CDC42; PROTEIN KINASE C; PROTEIN TYROSINE KINASE INHIBITOR; RADIXIN; RAF PROTEIN; RAS PROTEIN; RILOTUMUMAB; RPI 1; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SGX 523; STAT3 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CLEAR CELL SARCOMA; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; LUNG METASTASIS; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

EID: 79957961443     PISSN: 15743624     EISSN: 15743624     Source Type: Journal    
DOI: 10.2174/157436211795659991     Document Type: Article

References (66)

1. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440-3. (Pubitemid 19277521)
2. Gherardi E, Stoker M. Hepatocytes and scatter factor. Nature 1990; 346: 228. (Pubitemid 20227395)
3. Jiang WG, Davies G, Martin TA, et al. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo. Int J Mol Med 2005; 16: 723-8.
4. Jiang WG, Davies G, Martin TA, et al. Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res 2005; 11: 6012-9. (Pubitemid 41170333)
5. Kajiya K, Hirakawa S, Ma B, Drinnenberg I, Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 2005; 24: 2885-95. (Pubitemid 43079892)
6. Abounader R. Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. Expert Rev Anticancer Ther 2009; 9: 235-45.
7. Wojcik EJ, Sharifpoor S, Miller NA, et al. A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells. Oncogene 2006; 25: 2773-84.
8. You WK, McDonald DM. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 2008; 41: 833-9.
9. Giannini G, Noel J. Constitutive hepatocyte growth factor-receptor (HGF-R)/Met tyrosine kinase activation is associated with cellular transformation independently of mutations within its tyrosine kinase and c-terminal domains. Mol Biol Cell 2002; 13: 156A.
10. Kammula US, Kuntz EJ, Francone TD, et al. Molecular coexpression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007; 248: 219-28. (Pubitemid 46330555)
11. Bauer TW, Somcio RJ, Fan F, et al. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther 2006; 5: 1676-82. (Pubitemid 44323235)
12. Fischer OM, Giordano S, Comoglio PM, Ullrich A. Reactive oxygen species mediate Met receptor transactivation by G proteincoupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem 2004; 279: 28970-8. (Pubitemid 38915766)
13. Hecht M, Schulte JH, Eggert A, Wilting J, Schweigerer L. The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness. Carcinogenesis 2005; 26: 2105-15. (Pubitemid 41672198)
14. Kermorgant S, Parker PJ. c-Met signalling: spatio-temporal decisions. Cell Cycle 2005; 4: 352-5. (Pubitemid 41359712)
15. Kermorgant S, Zicha D, Parker PJ. PKC controls HGF-dependent c-Met traffic, signalling and cell migration. EMBO J 2004; 23: 3721-34. (Pubitemid 39389704)
16. Wu WS. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 2006; 25: 695-705.
17. Radisavljevic Z. AKT as locus of fragility in robust cancer system. J Cell Biochem 2008; 104: 2071-7.
18. Moumen A, Patane S, Porras A, Dono R, Maina F. Met acts on Mdm2 via mTOR to signal cell survival during development. Development 2007; 134: 1443-51. (Pubitemid 46706049)
19. Kanayama S, Yamada Y, Kawaguchi R, et al. Hepatocyte growth factor induces anoikis resistance by up-regulation of cyclooxygenase-2 expression in uterine endometrial cancer cells. Oncol Rep 2008; 19: 117-22. (Pubitemid 351176139)
20. Tang MK, Zhou HY, Yam JW, Wong AS. c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. Neoplasia 2010; 12: 128-38.
21. Moore AE, Greenhough A, Roberts HR, et al. HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells. Carcinogenesis 2009; 30: 1796-804.
22. Elliott BE, Hung WL, Boag AH, Tuck AB. The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can J Physiol Pharmacol 2002; 80: 91-102. (Pubitemid 34258657)
23. Zhang S, Zhau HE, Osunkoya AO, et al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer 2010; 9: 9.
24. Kermorgant S, Parker PJ. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol 2008; 182: 855-63.
25. Holgado-Madruga M, Emlet DR, Moscatello DK, Godwin AK, Wong AJ. A Grb2-associated docking protein in EGF- and insulinreceptor signalling. Nature 1996; 379: 560-4. (Pubitemid 26049586)
26. Holgado-Madruga M, Moscatello DK, Emlet DR, Dieterich R, Wong AJ. Grb2-associated binder-1 mediates phosphatidylinositol 3-kinase activation and the promotion of cell survival by nerve growth factor. Proc Natl Acad Sci U S A 1997; 94: 12419-24. (Pubitemid 27492543)
27. Bardelli A, Basile ML, Audero E, et al. Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. Oncogene 1999; 18: 1139-46. (Pubitemid 29085986)
28. Wang Z, Ge L, Wang M, Carr BI. Grb2-associated binder-1 plays a central role in the hepatocyte growth factor enhancement of hepatoma growth inhibition by K vitamin analog compound 5. Hepatology 2007; 46: 2003-13.
29. Kondo A, Hirayama N, Sugito Y, et al. Coupling of Grb2 to Gab1 mediates hepatocyte growth factor-induced high intensity ERK signal required for inhibition of HepG2 hepatoma cell proliferation. J Biol Chem 2008; 283: 1428-36.
30. Potempa S, Ridley AJ. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol Biol Cell 1998; 9: 2185-200. (Pubitemid 28373633)
31. Ueoka Y, Kato K, Wake N. Hepatocyte growth factor modulates motility and invasiveness of ovarian carcinomas via ras mediated pathway. Mol Cell Endocrinol 2003; 202: 81-8. (Pubitemid 36593397)
32. Esteve-Puig R, Canals F, Colome N, Merlino G, Recio JA. Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS One 2009; 4: e4771.
33. Kim AS, Kakalis LT, Abdul-Manan N, Liu GA, Rosen MK. Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature 2000; 404: 151-8. (Pubitemid 30154475)
34. Stella MC, Trusolino L, Comoglio PM. The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis. Mol Biol Cell 2009; 20: 642-57.
35. Pante G, Thompson J, Lamballe F, et al. Mitogen-inducible gene 6 is an endogenous inhibitor of HGF/Met-induced cell migration and neurite growth. J Cell Biol 2005; 171: 337-48. (Pubitemid 41540025)
36. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994; 77: 261-71. (Pubitemid 24138623)
37. Davies G, Martin TA, Ye L, et al. Phospholipase-C gamma-1 (PLCgamma-1) is critical in hepatocyte growth factor induced in vitro invasion and migration without affecting the growth of prostate cancer cells. Urol Oncol 2008; 26: 386-91. (Pubitemid 351885372)
38. Gual P, Giordano S, Williams TA, et al. Sustained recruitment of phospholipase C-gamma to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 2000; 19: 1509-18. (Pubitemid 30175672)
39. Hecht M, Papoutsi M, Tran HD, Wilting J, Schweigerer L. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas. Cancer Res 2004; 64: 6109-18. (Pubitemid 39129411)
40. Gotz R. Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression. Cancer Cell Int 2008; 8: 7.
41. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006; 116: 1582-95.
42. Hiscox S, Jiang WG. Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochem Biophys Res Commun 1999; 261: 406-11. (Pubitemid 29392489)
43. Davies G, Jiang WG, Mason MD. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cellcell dissociation and in vitro invasion. Clin Cancer Res 2001; 7: 3289-97. (Pubitemid 32963856)
44. Rasola A, Fassetta M, De Bacco F, et al. A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. Oncogene 2007; 26: 1078-87.
45. Ye M, Hu D, Tu L, et al. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Invest Ophthalmol Vis Sci 2008; 49: 497-504.
46. Ishibe S, Joly D, Liu ZX, Cantley LG. Paxillin serves as an ERKregulated scaffold for coordinating FAK and Rac activation in epithelial morphogenesis. Mol Cell 2004; 16: 257-67. (Pubitemid 39388840)
47. Comoglio PM, Boccaccio C, Trusolino L. Interactions between growth factor receptors and adhesion molecules: breaking the rules. Curr Opin Cell Biol 2003; 15: 565-71. (Pubitemid 37176965)
48. Kubota T, Taiyoh H, Matsumura A, et al. NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells. Clin Exp Metastasis 2009; 26: 447-56.
49. Syed DN, Afaq F, Sarfaraz S, et al. Delphinidin inhibits cell proliferation and invasion via modulation of Met receptor phosphorylation. Toxicol Appl Pharmacol 2008; 231: 52-60.
50. Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 2010; 11: 276-87.
51. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002; 16: 3074-86. (Pubitemid 35424194)
52. Harrison GM, Davies G, Martin TA, Jiang WG, Mason MD. Distribution and expression of CD44 isoforms and Ezrin during prostate cancer-endothelium interaction. Int J Oncol 2002; 21: 935-40.
53. Singh PK, Behrens ME, Eggers JP, et al. Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression. J Biol Chem 2008; 283: 26985-95.
54. Kongkham PN, Northcott PA, Ra YS, et al. An epigenetic genomewide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma. Cancer Res 2008; 68: 9945-53.
55. Matteucci E, Bendinelli P, Desiderio MA. Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis 2009; 30: 937-45.
56. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22: 309-25. (Pubitemid 36791889)
57. Naran S, Zhang X, Hughes SJ. Inhibition of HGF/MET as therapy for malignancy. Expert Opin Ther Targets 2009; 13: 569-81.
58. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15: 2207-14.
59. Davis IJ, McFadden AW, Zhang Y, et al. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res 2010; 70: 639-45.
60. Cassinelli G, Lanzi C, Petrangolini G, et al. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol Cancer Ther 2006; 5: 2388-97. (Pubitemid 44530476)
61. Nakagawa T, Tohyama O, Yamaguchi A, et al. E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci 2009.
62. Guessous F, Zhang Y, diPierro C, et al. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med Chem 2010; 10: 28-35.
63. Pillay V, Allaf L, Wilding AL, et al. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 2009; 11: 448-58.
64. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67: 4408-17. (Pubitemid 46815090)
65. Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009; 15: 59-67.
66. Youles M, Holmes O, Petoukhov MV, et al. Engineering the NK1 fragment of hepatocyte growth factor/scatter factor as a MET receptor antagonist. J Mol Biol 2008; 377: 616-22.